Categories: News

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:

Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)
First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)
Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)
Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET)

Investors interested in listening to the fourth quarter 2023 earnings conference call at 4:30 p.m. eastern time on Thursday, February 15, 2024, may do so by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Live and archived webcasts of all earnings events will also be made available at https://ir.shockwavemedical.com.

Dial-in information for future earnings calls will be provided at later dates.

About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in Europe. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Media Contact:
Scott Shadiow
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

Staff

Recent Posts

CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…

2 hours ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…

3 hours ago

inTouch Addresses $6.7 Billion Senior Loneliness Crisis with Launch of AI Conversational Companion for North America

Complements Family Interactions & Supports Sandwich Generation of Caregivers with Daily Phone Calls to Seniors…

3 hours ago

AI in Healthcare: MENA Region on the Verge of a Major Breakthrough

"Comprehensive Analysis of MENA's AI Healthcare Market: Emerging Opportunities and Challenges, with a Projected CAGR…

3 hours ago

Global Excel Acquires First Assistance to Strengthen Assistance Services and Expand in the Asia-Pacific Market

SHERBROOKE QC, July 2, 2025 /PRNewswire/ - Global Excel Management Inc. (Global Excel) is pleased…

3 hours ago

Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device

The evaluation will include 1,000 unique procedures across 20 centers worldwide to capture real-world evidence…

9 hours ago